Mobile

An international multi-center, open-label study to evaluate safety, tolerability, biodistribution (distribution in the body), dosimetry (to calculate the radiation exposure of patients) and preliminar...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-002867-41

An international multi-center, open-label study to evaluate safety, tolerability, biodistribution (distribution in the body), dosimetry (to calculate the radiation exposure of patients) and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor-positive neuroendocrine tumors (NETs). Eine internationale multizentrische, offene Studie zur Bewertung der Sicherheit, Verträglichkeit, Biodistribution (Verteilung im Körper), Dosimetrie (zur Berechnung der Strahlenbelastung der Patienten) und der vorläufigen Wirksamkeit von 177Lu-OPS201 für die Therapie Somatostatin-Rezeptor-positiver neuroendokriner Tumore (NETs)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and tolerability of peptide receptor radionuclide therapy (PRRT) with 177Lu-OPS201 administered in three cycles in patients with somatostatin receptor positive NETs (including phaechromocytomas and paragangliomas).

Critère d'inclusion

  • Neuroendocrine tumors (NETs)

Liens